Artifact
Aduhelm
Biogen's Alzheimer's drug (aducanumab), given accelerated approval in 2021.
Connections 2
produced by
involved in
- FDA accelerated approval of Aduhelm (2021) Primary record 2
Proof 2 sources
-
Maloney and Pallone Release Staff Report on Review, Approval, and Pricing of Biogen's Alzheimer's Drug Aduhelm, U.S. House Committee on Energy and Commerce, 29 Dec 2022.
Primary record
Biogen's Alzheimer's disease drug Aduhelm
-
Withdrawn: Non-Malignant Hematological, Neurological, and Other Disorder Indications (Accelerated Approval), U.S. Food and Drug Administration.
Primary record
Aduhelm (aducanumab-avwa) For the treatment of alzheimer’s disease 6/7/2021 11/1/2024
Page history 1 change
- Add 55 stories, each checked against its sources96e92fe6
Something wrong or missing? Tell us, with a source, or edit this page.